(Q37345854)

19 August 2017

1 reference

title

Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults (English)

1 reference

19 August 2017

0 references

0 references

Jean-Frédéric Colombel

series ordinal

1

object named as

Jean-Frédéric Colombel

1 reference

19 August 2017

language of work or name

1 reference

1 April 2008

1 reference

Expert Review of Gastroenterology & Hepatology

19 August 2017

published in

1 reference

19 August 2017

volume

2

1 reference

19 August 2017

issue

2

1 reference

19 August 2017

page(s)

163-176

1 reference

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Challenges and progress in pediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Review article: the burden of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Antagonist: Crohn's disease recurrence can be prevented after ileal resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Advances in the management of Crohn's disease: economic and clinical potential of infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Management of Crohn's disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Advances in therapeutic approaches to ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Advances in biologic therapy for ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Biological therapies in inflammatory bowel disease: top-down or bottom-up?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Adalimumab use in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

A critical assessment of new therapies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.2.163

21 January 2018

Identifiers

DOI

10.1586/17474124.2.2.163

1 reference

19 August 2017

1 reference